By Colin Kellaher

 

Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of the blockbuster blood-cancer drug Imbruvica in certain patients with chronic lymphocytic leukemia.

Janssen, which jointly develops and markets Imbruvica with AbbVie Inc., said the recommendation covers the drug in an oral fixed-duration combination with venetoclax for adults with previously untreated chronic lymphocytic leukemia, a type of cancer that starts from white blood cells in the bone marrow.

Janssen said the combination, if approved, would be the first all-oral, once daily, fixed-duration combination regimen for first-line treatment of the disease. The European Commission, which generally follows the CHMP's advice, will make a final decision on approval.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

June 24, 2022 08:36 ET (12:36 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
Von Jul 2022 bis Aug 2022 Click Here for more Johnson and Johnson Charts.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
Von Aug 2021 bis Aug 2022 Click Here for more Johnson and Johnson Charts.